Literature DB >> 16258795

[Primary prevention of coronary heart disease with aspirin].

W Kübler1, H Darius.   

Abstract

According to meta-analysis and the results of the two studies with the highest power, aspirin is effective in primary prevention of coronary heart disease. These beneficial effects, however, are at least partially out-weight by unwanted effects-such as intense gastrointestinal bleeding and hemorrhagic stroke. These side effects remain constant with increasing risk of coronary heart disease, whereas the protective effects increase. If an annual risk of coronary heart disease of < or =0.6% exists, aspirin is normally not indicated; for a risk of 0.7-1.4% the facts should be discussed with the patient. If a risk of > or =1.5% exists, aspirin should be given. Problems of aspirin therapy--such as "aspirin paradox" and "aspirin resistance"--have been documented for secondary prevention; they might, however, have likewise clinical implications in primary prevention.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16258795     DOI: 10.1007/s00392-005-1309-8

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  23 in total

1.  Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy.

Authors:  J H Alexander; R A Harrington; R H Tuttle; L G Berdan; A M Lincoff; J W Deckers; M L Simoons; A Guerci; J S Hochman; R G Wilcox; M M Kitt; P R Eisenberg; R M Califf; E J Topol; K Karsh; W Ruzyllo; J Stepinska; P Widimsky; J B Boland; P W Armstrong
Journal:  Am J Cardiol       Date:  1999-04-15       Impact factor: 2.778

2.  Aspirin for the primary prevention of cardiovascular events: recommendation and rationale.

Authors: 
Journal:  Ann Intern Med       Date:  2002-01-15       Impact factor: 25.391

3.  Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force.

Authors:  Michael Hayden; Michael Pignone; Christopher Phillips; Cynthia Mulrow
Journal:  Ann Intern Med       Date:  2002-01-15       Impact factor: 25.391

4.  Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework.

Authors: 
Journal:  Lancet       Date:  1998-01-24       Impact factor: 79.321

5.  Development of aspirin resistance in persons with previous ischemic stroke.

Authors:  C M Helgason; K M Bolin; J A Hoff; S R Winkler; A Mangat; K L Tortorice; L D Brace
Journal:  Stroke       Date:  1994-12       Impact factor: 7.914

6.  Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.

Authors:  Jean-Michel Gaspoz; Pamela G Coxson; Paula A Goldman; Lawrence W Williams; Karen M Kuntz; M G Myriam Hunink; Lee Goldman
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

7.  Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction.

Authors:  Wei C Lau; Lucy A Waskell; Paul B Watkins; Charlene J Neer; Kevin Horowitz; Amy S Hopp; Alan R Tait; David G M Carville; Kirk E Guyer; Eric R Bates
Journal:  Circulation       Date:  2003-01-07       Impact factor: 29.690

8.  Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.

Authors:  Jacqueline Saw; Steven R Steinhubl; Peter B Berger; Dean J Kereiakes; Victor L Serebruany; Danielle Brennan; Eric J Topol
Journal:  Circulation       Date:  2003-08-18       Impact factor: 29.690

9.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.

Authors:  Patricia A Gum; Kandice Kottke-Marchant; Patricia A Welsh; Jennifer White; Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

10.  Randomised trial of prophylactic daily aspirin in British male doctors.

Authors:  R Peto; R Gray; R Collins; K Wheatley; C Hennekens; K Jamrozik; C Warlow; B Hafner; E Thompson; S Norton
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.